Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

  • days left to enroll
  • participants needed
  • sponsor
    Samsung Medical Center
Updated on 25 January 2021
ejection fraction
breast cancer
her2/neu-positive breast cancer


Comparing preventive effect of myocardial global longitudinal strain-based cardioprotective stragety (angiotensin receptor blocker prophylaxis) with left ventricular ejection fraction-based strategy in breast cancer patients treated with adjuvant trastuzumab.


Despite the left ventricular global longitudinal strain (GLS) enables early prediction of trastuzumab-related cardiomyopathy, its clinical application has been hampered due to the lack of appropriate evaluation and treatment strategies. Therefore, we aimed to evaluate the effect of early intervention strategy (GLS-based cardiotoxicity monitoring and administration of candesartan) by comparing with conventional intervention strategy (left ventricular ejection fraction-based cardiotoxicity monitoring and administration of candesartan) in breast cancer patients who treated with adjuvant trastuzumab.

Condition prevention & control, Breast Cancer, Breast Cancer, Immunostimulant, Pharmaceutical Adjuvants, Diet and Nutrition, Chronic Diarrhea, Skin Wounds, Chronic Shoulder Pain, Vaginal Atrophy, Adverse Effects, Drugs, Injection Port, Breast Cancer - HER2 Positive, Anal Dysplasia, Primary Immunodeficiency, Pediatric Health, Near-Sighted Corrective Surgery, Cardiotoxicity, Peripheral Arterial Occlusive Disease, Breast Cancer Diagnosis, Brain Function, Cardiac Toxicity, Recurrent Respiratory Papillomatosis, Razor Bumps (Pseudofolliculitis Barbae), Metastatic Triple-Negative Breast Cancer, Trastuzumab, breast carcinoma, immunomodulator, immunostimulants, immunomodulators, immunological adjuvant, immunologic adjuvant, cancer, breast, prophylaxis, preventive treatment, prophylactic treatment
Treatment Candesartan
Clinical Study IdentifierNCT04429633
SponsorSamsung Medical Center
Last Modified on25 January 2021


Yes No Not Sure

Inclusion Criteria

Female aged 18 years
Pathologically confirmed HER2-positive breast cancer
Adjuvant treatment plan comprises at least 12 cycles of Trastuzumab
Baseline echocardiogram should be performed before starting trastuzumab
Cumulative anthracycline dose 300mg/m2
Written informed consent to participate in the study

Exclusion Criteria

History of hypersensitivity or alllergic reaction to the study medication
Metastatic breast cancer
Treatment with angiotensin converting enzyme(ACE) inhibitor , Angiotensin receptor blocker (ARB), beta-blocking agents, or diuretics
Patients with NCI/CTCAE grade 2 congestive heart failure, myocardial infarction, symptomatic left ventricular systolic dysfunction, heart's valve disease ( moderate), arrhythmias (Grade 3) < 12 months before enrollment
Pregnancy or breast feeding
Baseline systolic pressure < 90mmHg
Cumulative anthracycline dose > 300mg/m2
Serious concurrent illness
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note